Stimcell Energetics (STME) Net Income towards Common Stockholders Growth (1y) (2017 - 2024)
Stimcell Energetics (STME) Net Income towards Common Stockholders Growth (1y) (2017 - 2024) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -18.72% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 13.91% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 18.55% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 98.96% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 89.28% |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -30.10% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 121.14% |
| 10 | Stimcell Energetics | 5.85 Mn | 5.84 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2024 | -57.41% |
| Feb 29, 2024 | 42.84% |
| Nov 30, 2023 | 57.60% |
| Aug 31, 2023 | 50.25% |
| May 31, 2023 | 51.17% |
| Feb 28, 2023 | 1.11% |
| Nov 30, 2022 | 18.85% |
| Aug 31, 2022 | 35.37% |
| May 31, 2022 | 13.36% |
| Feb 28, 2022 | 33.25% |
| Nov 30, 2021 | 7.06% |
| Aug 31, 2021 | -18.96% |
| May 31, 2021 | 25.49% |
| Feb 28, 2021 | 49.76% |
| Nov 30, 2020 | 37.61% |
| Aug 31, 2020 | 17.97% |
| May 31, 2020 | 78.90% |
| Feb 29, 2020 | -319.80% |
| Nov 30, 2019 | -348.31% |
| Aug 31, 2019 | -202.72% |